In the dynamic landscape of health technology, bringing truly innovative medical devices to market is a complex journey fraught with challenges. Accelerators play a crucial role in nurturing these nascent companies, but not all accelerators are created equal. Paul Grand, CEO of MedTech Innovator, sheds light on his organization’s distinct approach to identifying and supporting promising MedTech startups, particularly those tackling high-risk, high-reward technologies.
More Than Just an Idea: Targeting Maturing Startups
MedTech Innovator positions itself as a “graduate school” for emerging companies. Unlike programs focused on early-stage ideation, MedTech Innovator seeks startups that have moved beyond the initial concept phase. Eligible companies must possess working prototypes with tangible evidence of their technology’s functionality, whether demonstrated through benchtop testing, cadaver studies, animal trials, or early human data. Additionally, these companies need a dedicated full-time team, even if just one person initially, and some initial funding. The focus is squarely on companies already committed to and progressing along the commercialization path.
Navigating the Path to Market with Expert Guidance
The accelerator employs a rigorous diagnostic process to evaluate applicant companies. They analyze potential pitfalls and risk points a company might encounter on its journey from its current stage through market launch and potential acquisition. To address these identified risks, MedTech Innovator pairs startups with relevant experts from their extensive network.
This evaluation process involves over 500 individuals, including representatives from major strategic players in the MedTech industry. Companies like Johnson & Johnson, Edwards Lifesciences, Dexcom, Gore, Olympus, Zimmer Biomet, and Nipro participate in vetting potential candidates, leveraging their deep domain knowledge and experience.
Embracing Transformational Potential in Emerging Tech
A key differentiator for MedTech Innovator is its willingness to support emerging technologies that may involve novel mechanisms of action, even if long-term evidence is still years away. Grand points to areas like brain-computer interfaces (BCIs) as examples where the potential for transformative impact outweighs the immediate lack of definitive proof. Senior leaders from large MedTech companies involved in the selection process are often the ones identifying these “game-changer” opportunities. While no company is entirely risk-free, the accelerator and its partners recognize that supporting these high-risk, high-reward ventures is essential for driving truly transformational, rather than merely incremental, advancements in healthcare.
Advice for Startups: Focus on the Real Need
Grand offers crucial advice to emerging technology companies seeking accelerator support: deeply study and target a significant market need. He cautions against pursuing the fastest or easiest regulatory approval path solely for the sake of getting to market quickly. Such an approach can be costly and may lead to a product nobody truly needs, hindering future funding rounds. Instead, startups should aim for the “big opportunity” where their technology can make a substantial difference. This requires developing the technology properly and raising sufficient capital to generate the necessary evidence for approval in the target market. Grand emphasizes that investors and the market are ultimately seeking solutions with significant potential impact.
To date, MedTech Innovator has successfully graduated over 700 companies, with an impressive 93% remaining in business, demonstrating the effectiveness of their tailored, risk-aware acceleration model.
